In our study , we conclude that FSH has a direct role in causing bone loss in hypogonadal mice. Our study does not, however, imply that estrogen and testosterone are not critical regulators of bone mass. To the contrary, we assert that sex steroids regulate bone formation and bone resorption, whereas FSH directly stimulates bone resorption. Problems in interpretation can arise when the phrase "bone loss" is used without defining its underlying etiology, that is, whether it is meant to signify reduced bone formation, increased bone resorption, or a combination of both. In their Correspondence, Dr. Seibel and colleagues correctly point out that bone loss occurs in hypogonadal hpg mice that lack gonadotropin-releasing hormone (GnRH) despite low or absent FSH. However, as their data show, this osteopenia arises, in major part, from a dramatic decrease in bone formation even in sexually immature 9-week-old mice. Although Sims et al. (2005) report that the number of bone-resorbing osteoclasts are modestly increased in hpg mice, we found that there is a reduction in osteoclast production and bone resorption in mature 4-month-old hpg mice (M.Z., unpublished data). In our Cell paper, we report a similar phenotype in 6-month-old FSHβ null mice and 4-month-old FSH receptor (FSHR) null mice . Therefore, we emphasize that in adult hpg mice or in mice lacking either FSHβ or FSHR, the absence of FSH signaling prevents the increase in bone resorption otherwise seen in hypogonadal states, such as after ovariectomy.
We concur with Dr. Seibel and colleagues that abrogation of FSH signaling will not protect against bone loss caused by a defect in the rate of bone formation. In our paper, we show that FSHRs are not expressed by the mature osteoblasts that form bone and that FSH does not affect the rate of bone formation. (It remains possible that there are subtle FSHdependent effects on bone remodeling consistent with the expression of FSHRs by mesenchymal stem cells.) We contend instead that the effects of FSH are mediated by osteoclasts, the cells that resorb bone. Both murine and human osteoclasts express FSHRs, and FSH stimulates production of osteoclasts, bone resorption, and the release of tumor necrosis factor α, which expands the number of osteoclast precursors Iqbal et al., 2006) . We therefore wish to point out that the loss of FSH signaling protects only against bone loss resulting from increased bone resorption, not from decreased bone formation.
We are aware that our mice lacking either FSHR or FSHβ have somewhat higher testosterone levels than wildtype littermates (Danilovich et al., 2000; Abel et al., 2003) . It is unlikely, however, that the elevated testosterone noted in female mice lacking either FSHR or FSHβ (1.4 and 1.6 nM, respectively) is sufficient to protect the skeleton via the androgen receptor. Even higher levels of testosterone (up to 4.9 nM) observed in mice lacking aromatase (the enzyme that converts testosterone to estrogen) do not prevent skeletal loss (see for example, Oz et al., 2000) . In the presence of high FSH levels in these mice, there is increased osteoclastic bone resorption and profound bone loss (Miyaura et al., 2001 ). Thus, FSH increases bone resorption despite high testosterone levels. In fact, the elevated levels of testosterone in female mice lacking either FSHβ or FSHR are far below typical levels in males (?20 nM). Furthermore, it is even less likely that the skeletal conservation in mice lacking either FSHβ or FSHR results from aromatization of testosterone to estrogen. The expression of the aromatase gene and/or serum estrogen levels are negligible in either of the hypogonadal mouse genotypes. Thus, we can only conclude that the skeletons of mice lacking either FSHβ or FSHR are conserved because of a lack of FSH, rather than elevated testosterone.
Finally, estrogen-deficient women with FSH levels greater than 40 international units per liter (IU/l) have significantly greater bone loss than women with FSH levels less than 40 IU/l (Devleta et al., 2004) . Furthermore, only in the former group is there a tight correlation between serum FSH and bone mineral density. Although this small comparison does not establish causality, it is consistent with the much larger Study of Women Across Nations (SWAN), which shows that changes in serum FSH rather than changes in serum estrogen correlate strongly with changes in bone mass during late peri-menopause. Likewise, increases in bone mass after estrogen replacement therapy correlate with decreased serum FSH levels (discussed in Sun et al., 2006) . Thus, even in humans, we speculate that, in addition to estrogen loss, the rise in FSH during late peri-menopause, after ovariectomy, or with aromatase inhibitors plays a major role in accelerating bone loss.
